BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30772476)

  • 1. Protection against fatal pneumonia through mucosal and subcutaneous immunization with the pneumococcal SP0148 protein.
    Huang J; Luo S; Huang M; Zhang T; Min Z; Liu C; Zhang Q; Yang J; Min X
    Microb Pathog; 2019 Apr; 129():206-212. PubMed ID: 30772476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal Immunization with the Commensal
    Shekhar S; Khan R; Schenck K; Petersen FC
    Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742
    [No Abstract]   [Full Text] [Related]  

  • 3. Subcutaneous immunization with the fusion protein ΔA146Ply-SP0148 confers protection against Streptococcus pneumoniae infection.
    Wang Y; Xia L; Wang G; Lu H; Wang H; Luo S; Zhang T; Gao S; Huang J; Min X
    Microb Pathog; 2022 Jan; 162():105325. PubMed ID: 34848296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung.
    Arévalo MT; Xu Q; Paton JC; Hollingshead SK; Pichichero ME; Briles DE; Girgis N; Zeng M
    FEMS Immunol Med Microbiol; 2009 Apr; 55(3):346-51. PubMed ID: 19291171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Combination of Recombinant Mycobacterium bovis BCG Strains Expressing Pneumococcal Proteins Induces Cellular and Humoral Immune Responses and Protects against Pneumococcal Colonization and Sepsis.
    Goulart C; Rodriguez D; Kanno AI; Converso TR; Lu YJ; Malley R; Leite LCC
    Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28768668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.
    Ferreira DM; Darrieux M; Silva DA; Leite LC; Ferreira JM; Ho PL; Miyaji EN; Oliveira ML
    Clin Vaccine Immunol; 2009 May; 16(5):636-45. PubMed ID: 19279169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immunization with rPotD reduces Streptococcus pneumoniae nasopharyngeal colonization in mice.
    Converso TR; Goulart C; Rodriguez D; Darrieux M; Leite LC
    Vaccine; 2017 Jan; 35(1):149-155. PubMed ID: 27884476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PrtA immunization fails to protect against pulmonary and invasive infection by Streptococcus pneumoniae.
    Hsu CF; Hsiao CH; Tseng SF; Chen JR; Liao YJ; Chen SJ; Lin CS; Sytwu HK; Chuang YP
    Respir Res; 2018 Sep; 19(1):187. PubMed ID: 30253765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide.
    Lu YJ; Forte S; Thompson CM; Anderson PW; Malley R
    Infect Immun; 2009 May; 77(5):2076-83. PubMed ID: 19255193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
    Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal immunization with recombinant chimeric pneumococcal protein and cell wall from immunobiotic bacteria improve resistance of infant mice to Streptococcus pneumoniae infection.
    Laiño J; Villena J; Suvorov A; Zelaya H; Ortiz Moyano R; Salva S; Alvarez S
    PLoS One; 2018; 13(11):e0206661. PubMed ID: 30395582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.
    Kataoka K; Fujihashi K; Oma K; Fukuyama Y; Hollingshead SK; Sekine S; Kawabata S; Ito HO; Briles DE; Oishi K
    Infect Immun; 2011 Jul; 79(7):2819-28. PubMed ID: 21536790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae.
    Briles DE; Hollingshead SK; Paton JC; Ades EW; Novak L; van Ginkel FW; Benjamin WH
    J Infect Dis; 2003 Aug; 188(3):339-48. PubMed ID: 12870114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
    Denoël P; Philipp MT; Doyle L; Martin D; Carletti G; Poolman JT
    Vaccine; 2011 Jul; 29(33):5495-501. PubMed ID: 21624422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against pneumococcal infection elicited by immunization with multiple pneumococcal heat shock proteins.
    Cao J; Zhang X; Gong Y; Zhang Y; Cui Y; Lai X; Yin Y; Li M; Li D; Zhang L
    Vaccine; 2013 Aug; 31(35):3564-71. PubMed ID: 23727004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
    Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
    Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.